January 31, 2024
Takeda Pharmaceutical said on January 29 that the US FDA has approved a label expansion of Gammagard Liquid as an intravenous immunoglobulin therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). With the approval,...read more